Stevanato Group S.p.A. (NYSE:STVN) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP reduced its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 88.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 318,565 shares of the company’s stock after selling 2,375,023 shares during the quarter. Wellington Management Group LLP owned approximately 0.11% of Stevanato Group worth $6,942,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the business. Conestoga Capital Advisors LLC boosted its holdings in Stevanato Group by 5.3% in the fourth quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company’s stock valued at $176,128,000 after purchasing an additional 407,086 shares in the last quarter. TimesSquare Capital Management LLC boosted its holdings in shares of Stevanato Group by 114.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company’s stock valued at $71,657,000 after buying an additional 1,756,100 shares in the last quarter. Artisan Partners Limited Partnership grew its position in shares of Stevanato Group by 28.7% in the 4th quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company’s stock valued at $51,333,000 after buying an additional 524,989 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Stevanato Group by 56.3% during the fourth quarter. Teacher Retirement System of Texas now owns 1,250,000 shares of the company’s stock worth $27,238,000 after purchasing an additional 450,000 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Stevanato Group during the fourth quarter worth approximately $20,239,000.

Stevanato Group Price Performance

Shares of STVN opened at €20.59 ($23.13) on Friday. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The stock’s 50 day moving average is €20.51 and its two-hundred day moving average is €20.61. Stevanato Group S.p.A. has a twelve month low of €16.56 ($18.61) and a twelve month high of €29.82 ($33.51). The firm has a market capitalization of $6.24 billion, a PE ratio of 43.81, a P/E/G ratio of 7.18 and a beta of 0.52.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). The firm had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Research analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on STVN. William Blair reiterated an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Wolfe Research began coverage on shares of Stevanato Group in a report on Friday, December 13th. They issued an “outperform” rating and a $28.00 target price for the company. UBS Group lowered their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a report on Friday, March 7th. Finally, Bank of America increased their price objective on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of €25.70 ($28.88).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.